Is grand multiparity a risk factor for the development of postmenopausal osteoporosis?
Nuri Peker,1 Özge Çeliker Tosun2 1Department of Obstetrics and Gynecology, İstinye University Bahçeşehir Liv Hospital, Istanbul, Turkey; 2School of Physiotherapy, Dokuz Eylul University, Izmir, Turkey Objective: In this study, we investigated the relationship between...
Guardado en:
Autores principales: | Peker N, Çeliker Tosun Ö |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/197f56d52f0b4d27b4c60e5afad4d148 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene
por: Luigi Gennari, et al.
Publicado: (2010) -
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
por: Paula Rackoff
Publicado: (2009) -
Olive oil in the prevention and treatment of osteoporosis after artificial menopause
por: Liu HL, et al.
Publicado: (2014) -
Effect of 6 months of whole body vibration on lumbar spine bone density in postmenopausal women: a randomized controlled trial
por: Lai CL, et al.
Publicado: (2013) -
BFH-OST, a new predictive screening tool for identifying osteoporosis in postmenopausal Han Chinese women
por: Ma Z, et al.
Publicado: (2016)